Beijing Jishuitan Hospital

Running trials

• Recruiting

  A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

  NCT07521007· Phase 2· Beijing Inno Medicine Co., Ltd.· Source

• Enrolling by invitation

  A Phase I Clinical Trial of CPU-YL01 Injection in Patients With Chronic Hepatitis B.

  NCT07918456· Phase 1· Jiangsu Chuangyuan Life Science and Technology Co., Ltd.· Source

• Not yet recruiting

  Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

  NCT07569757· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation

  NCT07444372· Beijing Anzhen Hospital· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

  NCT06797297· Phase 2· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Not yet recruiting

  Identification Of High-risk Coronary Plaques By Multimodal Intravascular Imaging

  NCT06681155· Chinese PLA General Hospital· Source

• Active, not recruiting

  Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

  NCT06332014· Phase 4· Amgen· Source

• Recruiting

  A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06574568· Phase 1· Excyte Biopharma Ltd· Source

• Active, not recruiting

  Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

  NCT04586660· Phase 4· Amgen· Source

• Active, not recruiting

  A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05572515· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT05479994· Phase 2· BeiGene· Source

• Active, not recruiting

  Study to Evaluate the Safety and Effectiveness of the REAL INTELLIGENCE™ CORI™ in Total Knee Arthroplasty (TKA) Procedure

  NCT04848896· Smith & Nephew, Inc.· Source

• Active, not recruiting

  A Study of NINLARO® in Chinese Adults With Multiple Myeloma

  NCT05013190· Takeda· Source

• Recruiting

  Evaluate the Safety and Clinical Activity of HH2853

  NCT04390737· Phase 1/2· Haihe Biopharma Co., Ltd.· Source

• Recruiting

  A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

  NCT04192344· Phase 1· Abbisko Therapeutics Co, Ltd· Source

• Recruiting

  China Health Big Data

  NCT03699228· Beijing Jishuitan Hospital· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease2 recruiting
• Multiple myeloma2 recruiting
• Atrial fibrillation1 recruiting
• Childhood cancers1 recruiting
• Follicular lymphoma1 recruiting
• Hepatitis B1 recruiting
• Obesity1 recruiting
• Obstructive sleep apnoea1 recruiting
• Osteoporosis1 recruiting
• Sarcoma1 recruiting

Closed trials

• Completed

  Real-world Study of Dedifferentiated Liposarcoma Patients in China

  NCT06115681· Boehringer Ingelheim· Source

• Terminated

  TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

  NCT06438783· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Completed

  AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

  NCT07030595· Phase 3· Alebund Pharmaceuticals· Source

• Terminated

  IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

  NCT05814536· Phase 1· AnHeart Therapeutics Inc.· Source

• Completed

  Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03)

  NCT05938374· Phase 2· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture

  NCT05352516· Phase 3· Shanghai Henlius Biotech· Source

• Terminated

  A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

  NCT04735575· Phase 1/2· Shanghai EpimAb Biotherapeutics Co., Ltd.· Source

• Completed

  A Study of Ninlaro in Real World Clinical Practice in China

  NCT04328662· Takeda· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Osteoarthritis57 works · 1 trial
• Osteoporosis38 works · 3 trials
• Ankylosing spondylitis7 works · 0 trials